CYTK - NASDAQ

Cytokinetics, Incorporated

CYTK·NASDAQ

$70.71

+0.041%

HealthcareBiotechnology

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$8.80B

EPS-6.5400

P/E Ratio-10.81

Earnings Date08/06/2026

1.42B

Assets

3Y+40.0%

5Y+167.0%

10Y+737.0%

2.08B

Total Liabilities

36%

3Y+86.0%

5Y+396.0%

10Y+2650.0%

-659.62M

Total Equity

387%

3Y+511.0%

5Y-682.0%

10Y-799.0%

Cytokinetics, Incorporated Funding & Solvency Profile

CYTK · NASDAQ

Current Assets

Cash & Cash Equivalents882.22M

Net Receivables0.00

Inventory0.00

Other Current Assets34.75M

Total Current Assets917 M

Non-Current Assets

Property, Plant & Equipment155.17M

Goodwill & Intangible Assets0.00

Long-Term Investments335.05M

Other Non-Current Assets17.34M

Total Non-Current Assets508 M

Total Assets

1.42B

Financial Health Analysis

Current Ratio

4.53x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Working Capital

715 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

64% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Cytokinetics, Incorporated Balance Sheet

CYTK • NASDAQ

Cytokinetics, Incorporated Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	882.2M	94.9M	113M	65.6M	112.7M	83M	36.4M	42.3M	125.2M	66.9M	65.1M	20.2M	20.2M	14.9M	18.8M	17.5M	25.6M	41.8M	116.6M	39.4M
Short-Term Investments	0.0	981.2M	501.8M	717M	359M	381.1M	188.7M	156.5M	143.7M	89.4M	46.4M	63M	57.6M	59.1M	30.2M	54.1M	89.2M	15M	3.2M	70.2M
Cash & Short-Term Investments	882.2M	1.1B	614.8M	782.6M	471.6M	464.1M	225.1M	198.7M	268.9M	156.2M	111.4M	83.2M	77.7M	74M	49M	71.6M	114.7M	56.9M	119.7M	109.5M
Net Receivables	0.0	16.7M	1.3M	147K	51.8M	4.4M	5.2M	6.8M	1.1M	24K	12K	46.6M	5K	4K	14K	46K	189K	261K	214K	42.2M
Accounts Receivables	0.0	16.7M	1.3M	147K	51.8M	4.4M	5.2M	2.2M	1.1M	24K	12K	46.6M	5K	4K	14K	46K	189K	261K	214K	42.1M
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	11.9M	0.0	12.2M	5.7M	3.5M	2.2M	4.3M	2.4M	1.5M	1.1M	1.4M	2.4M	2.1M	1.8M	2M	1.8M	2.1M	1.8M
Other Current Assets	34.8M	15.3M	0.0	12.5M	0.0	0.0	0.0	0.0	4.3M	0.0	0.0	0.0	0.0	2.4M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	917M	1.1B	628.1M	795.2M	535.7M	474.2M	233.8M	207.7M	274.3M	158.6M	113.1M	131.1M	79.3M	76.4M	51.1M	73.5M	116.9M	58.9M	122M	153.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	155.2M	141M	147.7M	163.2M	146.4M	16.3M	13.4M	3.2M	3.6M	3.6M	1.8M	1.6M	1.2M	997K	1.3M	2.3M	3.7M	5.1M	7.7M	9.2M
Long-Term Investments	335M	145.1M	40.5M	46.7M	152.1M	37M	42.7M	0.0	16.5M	7.7M	179K	0.0	2.5M	0.0	0.0	1.2M	1.7M	20M	20M	0.0
Other Non-Current Assets	17.3M	7.7M	8M	9.7M	7.2M	6.4M	0.0	300K	429K	200K	200K	200K	127K	127K	323K	967K	291K	3.5M	5.6M	6.7M
Total Non-Current Assets	507.6M	293.7M	196.3M	219.6M	305.6M	59.6M	56.1M	3.5M	20.5M	11.5M	2.1M	1.8M	3.9M	1.1M	1.6M	4.5M	5.7M	28.5M	33.4M	15.9M
Total Assets	1.4B	1.4B	824.3M	1B	841.3M	533.8M	289.8M	211.2M	294.8M	170.1M	115.2M	133M	83.2M	77.6M	52.8M	78M	122.6M	87.5M	155.4M	169.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	105.6M	20.4M	21.5M	25.6M	21.1M	8.1M	8.2M	3.8M	5.3M	4.2M	2.2M	1.4M	3.7M	2.2M	1.2M	1.1M	1.7M	1.4M	1.6M	2.8M
Accounts Payable	105.6M	20.4M	21.5M	25.6M	21.1M	8.1M	8.2M	3.8M	5.3M	4.2M	2.2M	1.4M	3.7M	2.2M	1.2M	1.1M	1.7M	1.4M	1.6M	2.8M
Accrued Expenses	0.0	55.3M	13.4M	22.3M	19.4M	7.5M	3.8M	15.8M	6.3M	18M	8.4M	5.4M	8.3M	4.9M	3.2M	5.4M	5.9M	7.2M	8.6M	7.5M
Short Term Debt	41.2M	11.5M	10.1M	958K	0.0	0.0	0.0	2.6M	0.0	2.5M	0.0	0.0	0.0	0.0	152K	833K	1.6M	2M	4.1M	3.7M
Capital Lease Obligations (Current)	19.1M	19M	17.9M	12.8M	14.9M	2.8M	4.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1K
Deferred Revenue	0.0	52.4M	0.0	0.0	0.0	0.0	0.0	15.8M	9.6M	8.1M	20.9M	17M	14.7M	76K	0.0	0.0	751K	12.3M	12.2M	12.2M
Other Current Liabilities	36.5M	21.1M	39.8M	22.9M	16.5M	12.8M	9.5M	66K	11.4M	415K	132K	52K	22K	76K	0.0	0.0	10.2M	0.0	22K	163K
Total Current Liabilities	202.5M	179.7M	102.7M	84.6M	71.9M	31.2M	26M	22.2M	32.4M	33.3M	31.6M	23.9M	26.7M	5.8M	4.6M	7.3M	20.2M	22.9M	26.4M	26.4M
NON-CURRENT LIABILITIES
Long Term Debt	1.1B	645.6M	607.4M	609.6M	142.8M	135.7M	129.3M	39.8M	31.8M	27.4M	14.6M	0.0	0.0	0.0	0.0	152K	985K	2.6M	4.6M	7.1M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	87M	87M	0.0	0.0	15M	15M	359K	16.6M	1.5M	0.0	0.0	0.0	0.0	12.2M	24.4M	29.7M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-359K	0.0	0.0	0.0	0.0	0.0	0.0	-12.2M	-24.4M	-29.7M
Other Non-Current Liabilities	657.8M	599.2M	380.2M	301.5M	183.5M	166.1M	143.3M	122.5M	105.7M	142K	359K	491K	542K	361K	3K	0.0	-985K	-2.6M	-4.6M	-7.1M
Total Non-Current Liabilities	1.9B	1.4B	1.1B	1B	525.6M	389.2M	274.7M	163.1M	152.5M	42.5M	15M	17M	2M	361K	3K	152K	985K	14.8M	29M	36.8M
Capital Lease Obligations	127.1M	131.6M	138.3M	139.7M	127.1M	3.2M	6.8M	771K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	2.1B	1.5B	1.2B	1.1B	597.5M	420.4M	300.8M	185.2M	185M	75.8M	46.6M	40.9M	28.7M	6.1M	4.6M	7.5M	21.2M	37.7M	55.5M	63.2M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4M	0.0	0.0	1K	0.0	0.0	0.0
Common Stock	123K	118K	102K	94K	84K	70K	59K	768.8M	54K	41K	40K	39K	31K	143K	75K	67K	61K	50K	49K	43K
Additional Paid-In Capital	2.8B	2.6B	1.7B	1.5B	1.5B	1.1B	853.3M	768.7M	755.5M	612.5M	603.1M	589.3M	537M	518.9M	456.6M	431.1M	412.7M	385.6M	379.7M	338.1M
Retained Earnings	-3.5B	-2.7B	-2.1B	-1.6B	-1.2B	-992.3M	-865M	-743.3M	-646.1M	-518.3M	-534.7M	-497.2M	-482.6M	-448.9M	-408.5M	-360.7M	-311.4M	-335.9M	-279.5M	-230.6M
Accumulated Other Comprehensive Income/Loss	630K	2.4M	-10K	-3.6M	-869K	149K	679K	500K	343K	137K	149K	-4K	7K	18K	3K	-4K	1K	18K	-330K	-1.2M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-119K	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	-659.6M	-135.4M	-386.3M	-107.9M	243.9M	113.4M	-10.9M	25.9M	109.8M	94.4M	68.6M	92.1M	54.4M	71.4M	48.2M	70.5M	101.4M	49.8M	99.9M	106.3M
Total Equity	-659.6M	-135.4M	-386.3M	-107.9M	243.9M	113.4M	-10.9M	25.9M	109.8M	94.4M	68.6M	92.1M	54.4M	71.4M	48.2M	70.5M	101.4M	49.8M	99.9M	106.3M
SUMMARY
Total Liabilities & Equity	1.4B	1.4B	824.3M	1B	841.3M	533.8M	289.8M	211.2M	294.8M	170.1M	115.2M	133M	83.2M	77.6M	52.8M	78M	122.6M	87.5M	155.4M	169.5M
Total Investments	335M	1.1B	542.3M	763.7M	511M	418M	231.3M	156.5M	160.2M	97M	46.5M	63M	60.1M	59.1M	30.2M	55.3M	90.8M	35M	23.2M	70.2M
Total Debt	1.3B	788.7M	755.8M	750.3M	269.9M	138.9M	136.1M	42.4M	31.8M	27.4M	14.6M	0.0	0.0	0.0	152K	985K	985K	4.6M	8.7M	10.8M
Net Debt	402M	693.8M	642.7M	684.7M	157.3M	56M	99.6M	157K	-93.4M	-39.5M	-50.4M	-20.2M	-20.2M	-14.9M	-18.7M	-16.5M	-24.6M	-37.2M	-107.9M	-28.6M
Shares Outstanding	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171	118,978,171

SEC Filings

CYTK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 27, 2026	May 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 08, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 17, 2026	May 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 17, 2026	February 17, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 19, 2025	2025	View Filing

Showing 1 to 10 of 667 filings

Related Guides

Blog Categories

Continue your CYTK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.